|
57
|
153
|
4cefA |
Interrogating hiv integrase for compounds that bind- a sampl challenge |
|
58
|
153
|
4cebA |
Interrogating hiv integrase for compounds that bind- a sampl challenge |
|
57
|
153
|
4ceoA |
Interrogating hiv integrase for compounds that bind- a sampl challenge |
|
55
|
153
|
4ce9A |
Interrogating hiv integrase for compounds that bind- a sampl challenge |
|
57
|
153
|
4cesA |
Interrogating hiv integrase for compounds that bind- a sampl challenge |
|
55
|
153
|
4cecA |
Interrogating hiv integrase for compounds that bind- a sampl challenge |
|
54
|
154
|
4cf9A |
Interrogating hiv integrase for compounds that bind- a sampl challenge |
|
57
|
153
|
4ck1A |
Interrogating hiv integrase for compounds that bind- a sampl challenge |
|
53
|
153
|
4cjeA |
Interrogating hiv integrase for compounds that bind- a sampl challenge |
|
54
|
153
|
4cj5A |
Interrogating hiv integrase for compounds that bind- a sampl challenge |
|
55
|
154
|
4cjlA |
Interrogating hiv integrase for compounds that bind- a sampl challenge |
|
53
|
153
|
4cjfA |
Interrogating hiv integrase for compounds that bind- a sampl challenge |
|
57
|
153
|
3zsqA |
Small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design |
|
59
|
153
|
3zsrA |
Small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design |
|
56
|
154
|
3zsoA |
Small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based design |
|
54
|
153
|
3zsyA |
Small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design |
|
57
|
153
|
3zswA |
Small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design |
|
53
|
153
|
3zt3A |
Small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design |
|
53
|
153
|
3zt0A |
Small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design |
|
56
|
153
|
3zt2A |
Small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design |
|
60
|
154
|
4ahsA |
Parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification |
|
58
|
153
|
4ahvA |
Parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification |
|
56
|
155
|
4ahuA |
Parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification |
|
58
|
153
|
3zsvA |
Small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design |
|
57
|
154
|
3zt4A |
Small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design |
|
55
|
153
|
3zszA |
Small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design |
|
54
|
153
|
3zt1A |
Small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design |
|
56
|
153
|
3zsxA |
Small molecule inhibitors of the ledgf site of hiv type 1 integrase identified by fragment screening and structure based drug design |
|
59
|
155
|
4ahrA |
Parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification |
|
59
|
156
|
4ah9A |
Parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification |
|
55
|
154
|
4ahtA |
Parallel screening of a low molecular weight compound library: do differences in methodology affect hit identification |
|
106
|
367
|
5mmaA |
Crystal structure of the prototype foamy virus (pfv) intasome in complex with magnesium and the insti xz379 (compound 5'g) |
|
73
|
216
|
5t3aA |
Maedi-visna virus (mvv) integrase ccd-ctd (residues 60-275) |
|
40
|
152
|
5oi2A |
Dissociation of biochemical and antiretroviral activities of integrase-ledgf allosteric inhibitors revealed by resistance of a125 polymorphic hiv-1 |
|
41
|
152
|
5oi3A |
Dissociation of biochemical and antiretroviral activities of integrase-ledgf allosteric inhibitors revealed by resistance of a125 polymorphic hiv-1 |
|
44
|
152
|
5oi5A |
Dissociation of biochemical and antiretroviral activities of integrase-ledgf allosteric inhibitors revealed by resistance of a125 polymorphic hiv-1 |
|
44
|
153
|
5kgwA |
Hiv1 catalytic core domain in complex with inhibitor: (2~{s})-2-[3-(3,4-dihydro-2~{h}-chromen-6-yl)-1-methyl-indol-2-yl]-2-[(2-methylpropan-2-yl)oxy]ethanoic acid |
|
52
|
154
|
5hrrA |
Hiv integrase catalytic domain containing f185k + a124n + t125s mutations complexed with gsk0002 |
|
48
|
153
|
5eu7A |
Crystal structure of hiv-1 integrase catalytic core in complex with fab |
|
49
|
211
|
5eu7C |
Crystal structure of hiv-1 integrase catalytic core in complex with fab |
|
49
|
233
|
5eu7E |
Crystal structure of hiv-1 integrase catalytic core in complex with fab |
|
52
|
162
|
5cz1A |
Crystal structure of the catalytic core domain of mmtv integrase |
|
49
|
153
|
4y1dA |
Cyclic hexapeptide cyc[ndpoppkid] in complex with hiv-1 integrase core domain |
|
50
|
152
|
4y1cA |
Cyclic hexapeptide cyc[ndpoppkid] in complex with hiv-1 integrase core domain |
|
49
|
155
|
4tsxA |
Hiv-1 integrase catalytic core domain mutant complexed with allosteric inhibitor |
|
54
|
153
|
4ovlA |
Interrogating hiv integrase for compounds that bind- a sampl challenge |
|
50
|
151
|
4pa1A |
Crystal structure of catalytic core domain of fiv integrase |
|
45
|
154
|
4o55A |
Hiv-1 integrase catalytic core domain complexed with allosteric inhibitor (2s)-tert-butoxy[6-(5-chloro-1h-benzimidazol-2-yl)-2,5-dimethyl-4-phenylpyridin-3-yl]ethanoic acid |
|
40
|
154
|
4o5bA |
Hiv-1 integrase catalytic core domain complexed with allosteric inhibitor (2s)-tert-butoxy[6-(5-chloro-1h-benzimidazol-2-yl)-2,5-dimethyl-4-phenylpyridin-3-yl]ethanoic acid |
|
55
|
155
|
4nyfA |
Hiv integrase in complex with inhibitor |
